William Blair research analyst Matt Phipps was quoted in Fierce Biotech, discussing how Bristol Myers Squibb’s deal with BioNTech to grow its vascular endothelial growth factor (VEGF) capabilities will impact the company and its investors.
“We have been skeptical on the ability of the VEGF mechanism to drive a clinically meaningful overall survival benefit, but [BMS] management maintained a ‘data look very interesting’ commentary, citing multiple studies showing significant PFS benefit and high activity from additional single-arm trials,” Phipps wrote in a note to investors that was cited by the publication.